Filter

Refine by Access

Refine By Collections

Refine by Type

Refine by Date

—
  • Print
  • Save

Search Results

You are looking at 51 - 55 of 55 items for :

  • "levofloxacin" x
  • All content x
Clear All

Ceftazidime–avibactam and ceftolozane–tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary

Acta Microbiologica et Immunologica Hungarica
Volume/Issue:
Volume 67: Issue 1
DOI:
https://doi.org/10.1556/030.2020.01152
Authors: Dustin O'Neall, Emese Juhász, Ákos Tóth, Edit Urbán, Judit Szabó, Szilvia Melegh, Katalin Katona, and Katalin Kristóf

), fluoroquinolones (testing ciprofloxacin and levofloxacin) and β-lactams (testing CAZ, cefepime (FEP), piperacillin/tazobactam (P/T)), including both meropenem and imipenem resistance, based on disk diffusion method according to EUCAST guidelines [ 20 ]. Bacterial

Open access

Characterization of macrolide-resistant non-invasive pneumococci in the pre-vaccine era in Serbia

Acta Microbiologica et Immunologica Hungarica
Volume/Issue:
Volume 65: Issue 4
DOI:
https://doi.org/10.1556/030.65.2018.035
Authors: Suncica Popovic, Mirjana Hadnadjev, Ina Gajic, Vera Mijac, Dusan Kekic, Aleksandra Smitran, Lazar Ranin, and Natasa Opavski

. C. , Kim , J. S. : Novel levofloxacin-resistant multidrug-resistant Streptococcus pneumoniae serotype 11A isolates, South Korea . Emerg Infect Dis 22 , 1978 – 1980 ( 2016 ). 10.3201/eid2211.151450 37

Restricted access

Resitance to b lactams and glycopeptides in staphylococci and sterptococci (A review)

Acta Microbiologica et Immunologica Hungarica
Volume/Issue:
Volume 48: Issue 3-4
DOI:
https://doi.org/10.1556/amicr.48.2001.3-4.8
Authors: Ferenc Rozgonyi, Eszter Ostorházy, Csaba L. Maródi, and et al.

333 Glatz, K., Szabó, D., Szabó, G., Boriszova, D., Rozgonyi, F. Emergence of extremly high penicillin and cefotaxime resistance and high level levofloxacin resistance in clinical isolates of

Restricted access

Review of therapeutic options for infections with carbapenem-resistant Klebsiella pneumoniae

European Journal of Microbiology and Immunology
Volume/Issue:
Volume 10: Issue 3
DOI:
https://doi.org/10.1556/1886.2020.00022
Authors: Rasmus G. Bandick, Soraya Mousavi, Stefan Bereswill, and Markus M. Heimesaat

received additional fosfomycin. c Ji et al. Combination therapy with fosfomycin, amikacin-levofloxacin, cefepime, cefoperazone-sulbactam, or meropenem, 52% of therapeutic schemes were combination therapies, otherwise tigecycline monotherapy. d Wunderink et

Open access

Advances in diagnosis and treatment of Helicobacter pylori infection

Acta Microbiologica et Immunologica Hungarica
Volume/Issue:
Volume 64: Issue 3
DOI:
https://doi.org/10.1556/030.64.2017.008
Authors: Reza Ranjbar, Payam Behzadi, and Shohreh Farshad

, levofloxacin, moxifloxacin, and metronidazole has been recognized between H. pylori strains. Some reports show the incredible increase of clarithromycin and metronidazole resistance rates up to 80%. On the other hand, the tetracycline and amoxicillin

Restricted access